Navigation Links
Discovery shows promise against severe side effects
Date:11/4/2010

November 4, 2010 (BRONX, NY) -- A team of scientists has found a way to eliminate a debilitating side effect associated with one of the main chemotherapy drugs used for treating colon cancer. The strategy used in their preclinical researchinhibiting an enzyme in bacteria of the digestive tractcould allow patients to receive higher and more effective doses of the drug, known as CPT-11 or Irinotecan.

The study, spearheaded by scientists at the University of North Carolina at Chapel Hill and involving collaborators at Albert Einstein College of Medicine of Yeshiva University and North Carolina Central University in Durham, is described in the November 5 issue of Science.

While the chemotherapy agent CPT-11 has proven useful in attacking colorectal tumors, it can also cause severe diarrhea - limiting the dosage that patients can tolerate and curbing the drug's potential effectiveness. The primary cause of the diarrhea is believed to be beta glucuronidase, an enzyme found in bacteria that live in the gastrointestinal tract. After the liver has rendered CPT-11 inert, the drug enters the intestine where it's reactivated by the beta glucuronidase of the gut bacteria. The revived CPT-11 irritates the intestine and causes severe diarrhea in up to 30 percent of patients who receive it.

To overcome this crippling side effect, the UNC researchers decided to look for compounds that would block the action of beta glucuronidase without eliminating the gut bacteria, which are important for human health.

"We need to retain our intestinal bacteria they help us digest food, make critical vitamins and protect us from infection," said Matthew R. Redinbo, Ph.D., who led the UNC research team, and is professor and chair of the chemistry department in the UNC College of Arts and Sciences and a member of the UNC Lineberger Comprehensive Cancer Center. "This targeted approach stops the one bacterial protein thought to cause the drug's devastating side effect, but without damaging the beneficial microbes or the intestines."


'/>"/>

Contact: Patric Lane
patric_lane@unc.edu
919-962-8596
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative
2. Cell survival protein discovery rewrites immune system story
3. Gene discovery could yield treatments for nearsightedness
4. A discovery by Dr. Andre Veillettes team could impact the treatment of autoimmune diseases
5. Discovery may aid search for anti-aging drugs
6. Discovery Moves Use of Stone Tools Back 800,000 Years
7. New discovery brings hope to treatment of incurable blood cancer
8. Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma
9. Discovery of Napoleon Hill Book Bound to Change Fate for Millions
10. B2Discovery: Entrepreneurs and researchers join forces to conquer cancer
11. Sun-induced skin cancer: new discovery permits doctors to assess genetic risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... has seen a significant spike in their clients' employee participation for their wellness ... health screening by implementing a high-deductible health plan with outcome-based deductible incentives. As ...
(Date:5/25/2016)... ... , ... Stern Environmental Group , of Secaucus, New Jersey, working in ... Stern’s Real Time Monitoring (RTM) Device. Stern Environmental Group will sell the first ... for use in dormitories, shelters, and nursing homes for real time bedbug monitoring in ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... has announced that Rudolfo (Rudy) Cifolelli has joined the company as Vice President ... and the development of U.S. and international sales in the rapidly expanding field ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... ... 24, 2016 , ... How to Write Error Free Procedures, **Presented by Ginette ... Human error is known to be the major cause of quality and production losses ... eliminated, many human performance problems can be prevented. , How to Write Error Free ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Non-invasive diagnostic test realizes the potential of ... be presented at Yissum’s booth, at IATI-BIOMED 2016 conference  ... the Hebrew University of Jerusalem announced today it ... MKI, the technology investment arm of Morris Kahn , ... early detection of multiple diseases by analyzing circulating DNA ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
(Date:5/23/2016)... Conn. , May 23, 2016   ... has entered into an agreement with Egalet Corporation ... patent claims. As part of the agreement the ... and will enable all three companies to develop ... properties. "This agreement reflects the commitment ...
Breaking Medicine Technology: